+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route of Administration, Fracture Type, End User - Global Forecast 2026-2032- Product Image
Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route of Administration, Fracture Type, End User - Global Forecast 2026-2032- Product Image
Sale

Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route of Administration, Fracture Type, End User - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5336746
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Osteoporosis Therapy & Fracture Healing Market is projected to reach USD 17.72 Billion in 2026. It is expected to continue growing at a CAGR of 8.77%, reaching USD 29.35 Billion by 2032.

Osteoporosis and fragility fractures remain a high-burden public health and commercial priority as populations age and post-fracture care costs rise. The International Osteoporosis Foundation reports that osteoporosis affects more than 200 million people worldwide, while one in three women and one in five men over age 50 are expected to experience an osteoporotic fracture during their lifetime. These fractures are clinically significant because hip, vertebral, and wrist fractures often trigger loss of mobility, repeat fractures, institutional care, and elevated mortality risk in older adults.

Anti-osteoporosis therapy and fracture healing strategies are moving beyond bone mineral density improvement alone. Current care pathways increasingly combine fracture risk assessment, dual-energy X-ray absorptiometry, fall-risk reduction, calcium and vitamin D optimization, antiresorptive drugs such as bisphosphonates and denosumab, and anabolic agents such as teriparatide, abaloparatide, and romosozumab for patients at very high fracture risk. For industry leaders, growth depends on demonstrating clinically meaningful fracture reduction, treatment persistence, safety monitoring, reimbursement value, and integration into post-fracture secondary prevention programs.

Transformative Shifts in the Osteoporosis Care Landscape

The osteoporosis treatment landscape is being reshaped by a stronger focus on secondary fracture prevention, early intervention after sentinel fractures, and patient stratification by absolute fracture risk. Fracture liaison services are expanding in several mature health systems because evidence shows that many patients who sustain fragility fractures do not receive osteoporosis evaluation or therapy. Closing this treatment gap is now a major clinical and market access priority.

Therapeutic sequencing is also changing. Long-term bisphosphonate use remains central due to proven fracture reduction and broad availability, but very-high-risk patients are increasingly considered for anabolic-first or anabolic-to-antiresorptive strategies to rapidly build bone and maintain gains. At the same time, real-world adherence, rare adverse events, renal limitations, injection burden, and discontinuation-related rebound fracture risk with denosumab are influencing prescribing decisions and product differentiation.

Cumulative Impact of Artificial Intelligence on Bone Health

Artificial intelligence is accumulating impact across osteoporosis detection, fracture-risk prediction, clinical workflow prioritization, and real-world evidence generation. AI-enabled imaging tools can support opportunistic screening from routine CT scans, vertebral fracture identification on radiographs, and automated bone health alerts for patients who might otherwise remain undiagnosed. These applications are especially relevant because vertebral fractures are frequently under-recognized despite being strong predictors of future fractures.

AI is also improving trial design and commercialization. Machine learning can help identify high-risk cohorts, model treatment persistence, detect safety signals in claims and electronic health record datasets, and personalize outreach for patients after a fracture. However, adoption depends on transparent validation, bias testing across sex and ethnicity, interoperability with hospital systems, and regulatory-grade clinical evidence demonstrating that AI improves outcomes rather than simply adding alerts.

Key Regional Insights for Osteoporosis Therapy

Asia-Pacific is becoming a pivotal growth region as China, India, Japan, South Korea, and Australia face rapid population aging and rising fracture burden. Japan has one of the world’s oldest populations and a mature osteoporosis treatment environment, while China and India offer large patient pools but continue to face underdiagnosis, uneven DXA access, and affordability constraints. Australia and South Korea are advancing guideline-based screening and post-fracture care, creating opportunities for therapies and digital tools that improve risk detection and adherence.

North America remains a high-value market due to established reimbursement systems, specialist networks, clinical guideline adoption, and broad use of DXA and fracture-risk assessment. Latin America, led by Brazil and Mexico, shows growing demand but faces gaps in screening infrastructure and access to advanced biologic therapies. Europe benefits from national fracture prevention programs, health technology assessment discipline, and strong academic research, while the Middle East is shaped by high vitamin D deficiency prevalence, diabetes burden, and expanding specialty care. Africa remains underpenetrated, with limited DXA capacity and fragmented access, but urban aging and noncommunicable disease growth are increasing the need for scalable osteoporosis screening and treatment models.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining strategic importance as urbanization, longer life expectancy, and expanding private healthcare systems increase demand for bone health diagnostics and pharmacologic treatment. The GCC is characterized by high healthcare investment, specialist hospital development, and a recognized burden of vitamin D deficiency, making it attractive for integrated fracture prevention programs and premium therapies. The European Union continues to influence global standards through centralized regulatory pathways, pharmacovigilance expectations, comparative effectiveness requirements, and national reimbursement reviews.

BRICS economies combine large patient populations, local manufacturing scale, and increasing clinical trial participation, although access remains uneven across income groups and public insurance systems. G7 markets lead in innovation, real-world evidence adoption, AI-enabled diagnostics, and advanced biologic use, but they also impose rigorous cost-effectiveness expectations. NATO-aligned markets add relevance from a supply-chain resilience perspective, as continuity of sterile injectables, biologics, active pharmaceutical ingredients, and orthopedic trauma care has become a higher priority after recent global disruptions.

Key Country Insights in Major Osteoporosis Markets

The United States remains one of the most commercially significant markets, supported by clinical guidelines, Medicare coverage for bone density testing in eligible patients, and high use of branded and generic therapies; however, treatment rates after fragility fracture remain a persistent gap. Canada emphasizes evidence-based prescribing and coordinated care, while Mexico and Brazil show rising demand as aging populations and private healthcare investment increase, though diagnosis rates and access to specialty therapy vary widely.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by national reimbursement systems, fracture liaison service adoption, and health technology assessment scrutiny. Russia has a sizable aging population and demand for cost-effective antiresorptives, but access can differ regionally. In Asia-Pacific, China and India represent scale and long-term growth potential, Japan provides a mature market with strong geriatric demand, South Korea is advancing digital healthcare integration, and Australia benefits from guideline-driven osteoporosis management and structured post-fracture care initiatives.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and services that prove fracture reduction, improve adherence, and fit seamlessly into post-fracture clinical workflows. Anabolic-first strategies for very-high-risk patients, denosumab transition planning, renal-safe options, and patient support programs should be positioned with clear evidence on outcomes and persistence.

Organizations should also invest in partnerships with fracture liaison services, orthopedic networks, radiology groups, and digital health vendors to capture patients at the point of fracture or incidental imaging. Market access teams should build region-specific value dossiers using real-world evidence, cost-offset models for avoided hip fractures, and clear safety-management protocols to support payer confidence.

Research Methodology

This executive summary is grounded in a structured research methodology combining peer-reviewed clinical literature, osteoporosis treatment guidelines, regulatory documents, public health datasets, and validated epidemiological references from recognized organizations such as the International Osteoporosis Foundation, WHO-linked resources, national health agencies, and major medical societies. Evidence was screened for clinical relevance to anti-osteoporosis therapy, fracture healing, fracture prevention, and real-world treatment pathways.

The analysis further applies market triangulation across epidemiology, reimbursement context, product class dynamics, guideline adoption, and regional healthcare infrastructure. Insights were validated for consistency with current clinical standards, including the established role of antiresorptive therapies, the use of anabolic therapies in high-risk populations, and the growing role of AI-enabled imaging and risk stratification.

Conclusion

Anti-osteoporosis therapy and fracture healing are entering a more integrated era in which fracture prevention, post-fracture intervention, AI-enabled detection, and personalized treatment sequencing are converging. The market is supported by strong demographic demand and a substantial untreated patient population, but growth will depend on improving diagnosis, adherence, safety management, and payer-recognized value.

Organizations that combine evidence-backed therapies with digital screening, real-world outcome tracking, and scalable fracture liaison partnerships will be best positioned to capture growth. The strongest competitive advantage will come from converting osteoporosis care from episodic prescription activity into a coordinated, data-driven fracture prevention ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Therapy Type
7.1. Bisphosphonates
7.1.1. Alendronate
7.1.2. Ibandronate
7.1.3. Risedronate
7.1.4. Zoledronic Acid
7.2. Hormone Replacement Therapy
7.2.1. Combined Hormone Therapy
7.2.2. Estrogen Therapy
7.3. Monoclonal Antibodies
7.3.1. Denosumab
7.3.1.1. Prolia
7.3.1.2. Xgeva
7.3.2. Romosozumab
7.4. Parathyroid Hormone Analogues
7.4.1. Abaloparatide
7.4.2. Teriparatide
7.5. Selective Estrogen Receptor Modulators
7.5.1. Bazedoxifene
7.5.2. Raloxifene
8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration
8.1. Injectable
8.1.1. Intravenous
8.1.2. Subcutaneous
8.2. Oral
9. Anti-Osteoporosis Therapy & Fracture Healing Market, by Fracture Type
9.1. Hip
9.2. Spinal
9.3. Wrist
10. Anti-Osteoporosis Therapy & Fracture Healing Market, by End User
10.1. Homecare
10.2. Hospitals
10.3. Specialty Clinics
11. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market
12. North America Anti-Osteoporosis Therapy & Fracture Healing Market
13. Latin America Anti-Osteoporosis Therapy & Fracture Healing Market
14. Europe Anti-Osteoporosis Therapy & Fracture Healing Market
15. Middle East Anti-Osteoporosis Therapy & Fracture Healing Market
16. Africa Anti-Osteoporosis Therapy & Fracture Healing Market
17. ASEAN Anti-Osteoporosis Therapy & Fracture Healing Market
18. GCC Anti-Osteoporosis Therapy & Fracture Healing Market
19. European Union Anti-Osteoporosis Therapy & Fracture Healing Market
20. BRICS Anti-Osteoporosis Therapy & Fracture Healing Market
21. G7 Anti-Osteoporosis Therapy & Fracture Healing Market
22. NATO Anti-Osteoporosis Therapy & Fracture Healing Market
23. United States Anti-Osteoporosis Therapy & Fracture Healing Market
24. Canada Anti-Osteoporosis Therapy & Fracture Healing Market
25. Mexico Anti-Osteoporosis Therapy & Fracture Healing Market
26. Brazil Anti-Osteoporosis Therapy & Fracture Healing Market
27. United Kingdom Anti-Osteoporosis Therapy & Fracture Healing Market
28. Germany Anti-Osteoporosis Therapy & Fracture Healing Market
29. France Anti-Osteoporosis Therapy & Fracture Healing Market
30. Russia Anti-Osteoporosis Therapy & Fracture Healing Market
31. Italy Anti-Osteoporosis Therapy & Fracture Healing Market
32. Spain Anti-Osteoporosis Therapy & Fracture Healing Market
33. China Anti-Osteoporosis Therapy & Fracture Healing Market
34. India Anti-Osteoporosis Therapy & Fracture Healing Market
35. Japan Anti-Osteoporosis Therapy & Fracture Healing Market
36. Australia Anti-Osteoporosis Therapy & Fracture Healing Market
37. South Korea Anti-Osteoporosis Therapy & Fracture Healing Market
38. Competitive Landscape
38.1. Market Concentration Analysis, 2025
38.1.1. Concentration Ratio (CR)
38.1.2. Herfindahl Hirschman Index (HHI)
38.2. Recent Developments & Impact Analysis, 2025
38.3. Product Portfolio Analysis, 2025
38.4. Benchmarking Analysis, 2025
39. Company Profiles
39.1. Amgen Inc.
39.2. Eli Lilly and Company
39.3. F. Hoffmann-La Roche Ltd.
39.4. GSK plc
39.5. Healthy Life Pharma Pvt. Ltd.
39.6. Johnson & Johnson Services, Inc.
39.7. Manus Aktteva Biopharma LLP
39.8. Merck & Co., Inc.
39.9. Novartis AG
39.10. Pfizer Inc.
39.11. Salvavidas Pharmaceutical Private Limited
39.12. Sanofi S.A.
39.13. Taj Pharmaceuticals
39.14. Taj Pharmaceuticals Limited
39.15. Teva Pharmaceuticals Industries Ltd
List of Figures
FIGURE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 35. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 47. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 48. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BISPHOSPHONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BISPHOSPHONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BISPHOSPHONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ALENDRONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ALENDRONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ALENDRONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IBANDRONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IBANDRONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IBANDRONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RISEDRONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RISEDRONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RISEDRONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ZOLEDRONIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ZOLEDRONIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ZOLEDRONIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HORMONE REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HORMONE REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HORMONE REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL COMBINED HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL COMBINED HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL COMBINED HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DENOSUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DENOSUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DENOSUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PROLIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PROLIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PROLIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL XGEVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL XGEVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL XGEVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ROMOSOZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ROMOSOZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ROMOSOZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PARATHYROID HORMONE ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PARATHYROID HORMONE ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PARATHYROID HORMONE ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ABALOPARATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ABALOPARATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ABALOPARATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL TERIPARATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TERIPARATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TERIPARATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SELECTIVE ESTROGEN RECEPTOR MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SELECTIVE ESTROGEN RECEPTOR MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SELECTIVE ESTROGEN RECEPTOR MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BAZEDOXIFENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BAZEDOXIFENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BAZEDOXIFENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RALOXIFENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RALOXIFENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RALOXIFENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SPINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SPINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SPINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL WRIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL WRIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL WRIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 138. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 140. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 141. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 142. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 161. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 162. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 164. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 165. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 166. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 172. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 174. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 175. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 176. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 177. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 178. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 179. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 181. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 182. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 184. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 185. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 186. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 187. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 188. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 189. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 190. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 191. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 193. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 194. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 208. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 209. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 210. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 211. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 212. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 213. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 214. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 215. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 217. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 218. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 220. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 221. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 222. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 223. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 224. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 225. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 226. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 227. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 229. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 230. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 232. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 233. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 234. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 235. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 236. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 237. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 238. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 239. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 241. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 242. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 256. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 257. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 258. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 259. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 260. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 261. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 262. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 263. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 264. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 265. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 266. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 269. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 270. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 271. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 272. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 273. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 274. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 275. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 277. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 278. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 280. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 281. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 282. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 283. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 284. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 285. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
TABLE 286. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 287. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 288. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 289. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
TABLE 290. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHY

Companies Mentioned

The companies featured in this Anti-Osteoporosis Therapy & Fracture Healing market report include:
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Healthy Life Pharma Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Private Limited
  • Sanofi S.A.
  • Taj Pharmaceuticals
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals Industries Ltd

Table Information

Report AttributeDetails
No. of Pages183
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 17.72 Billion
Forecasted Market Value ( USD ) by 2032 $ 29.35 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 188 Pages
  • Global
From
Osteoporosis Drugs Market by Drug Class, Route of Administration, Dosage Form, Mechanism of Action, Patient Gender, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Osteoporosis Drugs Market by Drug Class, Route of Administration, Dosage Form, Mechanism of Action, Patient Gender, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Osteoporosis Treatment Market Report 2026 - Product Image

Osteoporosis Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2026-2034 - Product Image

Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2026-2034

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.